Regulation of human gamma-interferon and beta-interferon gene expression in PHA-activated lymphocytes. 1986

C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff

Two interferon (IFN) messengers were synthesized in phytohemagglutinin (PHA)-activated lymphocytes: IFN-gamma mRNA and a messenger hybridizing with the IFN-beta 2 probe. They were induced rapidly and declined at a stage when overall RNA was still efficiently transcribed. The IFN-beta 2 mRNA (15S) present in the lymphocytes was slightly different from its fibroblastic counterpart (14S). The kinetics of the accumulation and decay of both lymphocyte IFN messengers differed when assessed by hybridization with the two IFN probes, IFN-gamma mRNA was not detected before mitogenic activation and accumulated for up to 15 h postactivation, while IFN-beta 2 mRNA accumulated even in the absence of PHA activation for up to 5 h, even though the activation raised the IFN-beta 2 mRNA level at 5 h. The disappearance of IFN messengers was prevented when cycloheximide was added 5 h after PHA activation, when the transcription of both messengers had already been turned on, suggesting the presence of the repressor mechanism proposed for IFN-beta 1 and IFN-beta 2 mRNAs in fibroblasts. In the absence of PHA activation, cycloheximide did not induce IFN-beta 2 mRNA transcription as it did in fibroblasts and moreover prevented the accumulation of the messenger observed in the control cells. In contrast to IFN-beta 2 mRNA, cycloheximide treatment of lymphocytes produced a slight accumulation of IFN-gamma mRNA. This accumulation was already detectable 6 h posttreatment and its level remained unchanged for up to 24 h. Addition of actinomycin D, 5 h after PHA activation, did not impair the shut off and accelerated the decay of IFN messengers.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
January 1999, Antiviral research,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
May 1991, Scandinavian journal of immunology,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
January 1992, Scandinavian journal of immunology,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
May 1996, Infection and immunity,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
December 1985, Proceedings of the National Academy of Sciences of the United States of America,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
August 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
June 1992, Journal of neuroimmunology,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
September 1995, Neuroscience letters,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
September 2001, Blood,
C Vaquero, and J Sanceau, and J Weissenbach, and F Beranger, and R Falcoff
September 1989, The Journal of experimental medicine,
Copied contents to your clipboard!